Sign-on & Comment Letters

LUNGevity ensures that the lung cancer community’s interests are represented and heard through a variety of vehicles, including submitting and signing letters to legislators and regulators.

Access to Care

Food and Drug Administration (FDA)

Institute for Clinical and Economic Review (ICER)

National Institutes of Health (NIH)

Patient Support

Promoting incorporation of more patient support in policymaking

Friends of the Cancer Policy Institute letter 01/31/2017

Prescription Drug User Fee Act (PDUFA)

Requests to include measures to increase public awareness of clinical trials in the PDUFA reauthorization process

Coalition for Clinical Trials Awareness letter 04/07/17

Regulation of Lab-Developed-Tests (LTDs)

Urging policymakers to include FDA involvement in the regulation of LDTs

Letter to House 04/01/16

Letter to Senate 04/01/2016

Letter to House 01/24/2017

Letter to Senate 01/24/2017

Research Funding


Support for coverage for screening to promote early detection of lung cancer

Letter to CMS supporting screening

21st Century Cures

Support for the 21st Century Cures Act, a federal patient-focused bill that would advance the discovery and development of treatments, strengthen the patient voice in the research and regulatory environment, increase funding, and encourage innovation

Letter to House and Senate